Literature DB >> 20503998

The pivotal role of chelation as a stereochemical control element in non-Evans anti aldol product formation.

C B Shinisha1, Raghavan B Sunoj.   

Abstract

The origin of stereoselective formation of Evans syn and non-Evans anti aldol products in the reaction between titanium enolate derived from N-succinyloxazolidinone and benzaldehyde is established by using transition-state modeling. The chelated transition-state model is found to hold the key to otherwise less likely non-Evans anti aldol product, whereas the nonchelated model offers a convincing rationalization toward Evans syn aldol product. The computed results are in agreement with the reported experimental observations.

Entities:  

Year:  2010        PMID: 20503998     DOI: 10.1021/ol100969f

Source DB:  PubMed          Journal:  Org Lett        ISSN: 1523-7052            Impact factor:   6.005


  5 in total

1.  Evans Enolates: Solution Structures of Lithiated Oxazolidinone-Derived Enolates.

Authors:  Evan H Tallmadge; David B Collum
Journal:  J Am Chem Soc       Date:  2015-10-05       Impact factor: 15.419

2.  Structures and Reactivities of Sodiated Evans Enolates: Role of Solvation and Mixed Aggregation on the Stereochemistry and Mechanism of Alkylations.

Authors:  Zirong Zhang; David B Collum
Journal:  J Am Chem Soc       Date:  2018-12-17       Impact factor: 15.419

3.  (Diisopinocampheyl)borane-mediated reductive aldol reactions of acrylate esters: enantioselective synthesis of anti-aldols.

Authors:  Christophe Allais; Philippe Nuhant; William R Roush
Journal:  Org Lett       Date:  2013-07-25       Impact factor: 6.005

4.  Wittig Rearrangements of Boron-Based Oxazolidinone Enolates.

Authors:  Zirong Zhang; David B Collum
Journal:  J Org Chem       Date:  2019-08-15       Impact factor: 4.354

5.  Evans Enolates: Structures and Mechanisms Underlying the Aldol Addition of Oxazolidinone-Derived Boron Enolates.

Authors:  Zirong Zhang; David B Collum
Journal:  J Org Chem       Date:  2017-07-07       Impact factor: 4.354

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.